S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)

• Meletios A. Dimopoulos,
• Vania Hungria,
• Atanas Radinoff,
• Sosana Delimpasi,
• Gabor Mikala,
• Tamas Masszi,
• Jian LI,
• Marcelo Eduardo Capra,
• Morio Matsumoto,
• Neal Sule,
• Mary LI,
• Astrid Mckeown,
• Wei He,
• Shelley Bright,
• Brooke Currie,
• Julia Boyle,
• Joanna Opalinska,
• Katja Weisel

Affiliations

Meletios A. Dimopoulos

1 National and Kapodistrian University of Athens School of Medicine, Athens, Greece

Vania Hungria

2 Department of Hematology, Clinica São Germano, Sao Paulo, Brazil

Atanas Radinoff

3 University Hospital “St Ivan Rilski” EAD, Sofia, Bulgaria

Sosana Delimpasi

4 General Hospital Evangelismos, Athens, Greece

Gabor Mikala

5 South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary

Tamas Masszi

6 Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary

Jian LI

7 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Marcelo Eduardo Capra

8 Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil

Morio Matsumoto

9 National Hospital Organization, Shibukawa Medical Center, Shibukawa, Japan

Neal Sule

10 GSK, Upper Providence, PA, United States

Mary LI

10 GSK, Upper Providence, PA, United States

Astrid Mckeown

11 GSK, Stevenage, England, United Kingdom

Wei He

12 GSK, Waltham, MA, United States

Shelley Bright

10 GSK, Upper Providence, PA, United States

Brooke Currie

13 GSK, Rockville, MD, United States

Julia Boyle

14 GSK, London, United Kingdom

Joanna Opalinska

10 GSK, Upper Providence, PA, United States

Katja Weisel

15 University Medical Center of Hamburg-Eppindorf, Hamburg, Germany